KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 6 years of Other financing activities data on record, last reported at $73.2 million in Q3 2025.

  • For Q3 2025, Other financing activities changed N/A year-over-year to $73.2 million; the TTM value through Sep 2025 reached $235.6 million, up 45.09%, while the annual FY2023 figure was $162.4 million, 9666.39% up from the prior year.
  • Other financing activities reached $73.2 million in Q3 2025 per AMRX's latest filing, down from $161.9 million in the prior quarter.
  • Across five years, Other financing activities topped out at $161.9 million in Q4 2023 and bottomed at $41000.0 in Q3 2022.
  • Average Other financing activities over 3 years is $58.9 million, with a median of $36.9 million recorded in 2023.
  • The widest YoY moves for Other financing activities: up 1221.95% in 2023, down 1221.95% in 2023.
  • A 3-year view of Other financing activities shows it stood at $41000.0 in 2022, then surged by 394712.2% to $161.9 million in 2023, then crashed by 54.76% to $73.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $73.2 million in Q3 2025, $161.9 million in Q4 2023, and $542000.0 in Q3 2023.